Blog - Advanced Medicine In China

3 months ago

Indications for Kymriah Approval in Europe

Indications for Kymriah Approval in Europe In early May 2022, Novartis announced that the European Commission (EC) has approved the CAR-T cell therapy Kymriah (tisagenlecleucel) for the treatment o...

3 months ago

Real-World Experience Comparing Kymriah and Yescarta for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) in 307 Cases

Real-World Experience Comparing Kymriah and Yescarta for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) in 307 Cases Several CAR-T products have been approved for the treatme...

3 months ago

Kite Pharma Yescarta (Axicabtagene Ciloleucel) Product Information

Kite Pharma Yescarta (Axicabtagene Ciloleucel) Product Information Generic Name: Axicabtagene Ciloleucel Injection Brand Name: Yescarta Indications 1. Large B-Cell Lymphoma Yescarta is indicated fo...

3 months ago

Sustained 7-Month CR, Liver Extramedullary Disease Disappearance: Equecabtagene Autoleucel Brings High-Quality Survival Hope to Ultra-High-Risk RRMM Patients with Extramedullary Disease

### Sustained 7-Month CR, Liver Extramedullary Disease Disappearance: Equecabtagene Autoleucel Brings High-Quality Survival Hope to Ultra-High-Risk RRMM Patients with Extramedullary Disease RRMM Pa...

3 months ago

What are the adverse reactions after CAR-T cell reinfusion?

Interpretation of Hot Topics Conerning Mutiple Myeloma Patients: “What are the adverse reactions after CAR-T cell reinfusion?” Process Diagram for Myeloma Patients Receiving CAR-T ...

3 months ago

Maximum Intention-to-Treat Analysis of Kite Pharma’s Tecartus (Brexucabtagene autoleucel) for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Maximum Intention-to-Treat Analysis of Kite Pharma’s Tecartus (Brexucabtagene autoleucel) for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Patients with relapsed/refrac...

3 months ago

What are Kite FDA Approved CAR-T Cell Therapies

What are Kite FDA Approved CAR-T Cell Therapies Introduction to Kite Company Kite, a pioneering biotechnology company, has firmly established itself as a leader in the development of novel cancer i...

3 months ago

Kite CAR-T Approval Overview

Kite CAR-T Approval Overview Introduction to Kite Pharma Kite Pharma, a subsidiary of Gilead Sciences, is a leading biopharmaceutical company focused on developing innovative cancer immunotherapies...

3 months ago

2024 EBMT : China’s First RRMM CAR-T Therapy Equecabtagene Autoleucel: Efficacy Unaffected by Patients’ Baseline sBCMA Plasma Levels

2024 EBMT : China’s First RRMM CAR-T Therapy Equecabtagene Autoleucel: Efficacy Unaffected by Patients’ Baseline sBCMA Plasma Levels RRMM In recent years, CAR-T cell therapy targeting B...

3 months ago

2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients

**2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients** Multiple Myeloma Multiple Myeloma (MM) is a malig...

3 months ago

#EBMT / #EHA Leading the Frontiers of Medicine: China’s Top Medical Expert Explains the Groundbreaking CAR-T Cell Therapy

#EBMT / #EHA Leading the Frontiers of Medicine: China’s Top Medical Expert Explains the Groundbreaking CAR-T Cell Therapy Expert:**Huang He** Chief Physician and Doctoral Supervisor. C...

3 months ago

Hodgkin Lymphoma CAR-T Cell Therapy BRD-01 Clinical Trial Application Approved in China

Hodgkin Lymphoma CAR-T Cell Therapy BRD-01 Clinical Trial Application Approved in China On July 10, 2024, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administrat...

Menu

Our Blog